In fact, several studies have reported a predictable and dose-proportionate PK behavior of EPAG in ITP patients (Gibiansky et al., 2011; Matthys et al., 2011; Wire et al., 2018). The gene discussed is DIAPH2-AS1; the disease is autoimmune thrombocytopenic purpura.